慢性肾脏病中生长分化因子15的关联研究
NURTuRE-CKD前瞻性多中心队列纳入2996例非透析依赖CKD患者,基线测量循环GDF-15并评估食欲。结果显示GDF-15中位浓度2503 pg/ml,每翻倍与食欲差、肌少症标志物、CKD进展及全因死亡独立相关。
要点
- GDF-15每翻倍与食欲差风险增加独立相关(OR 1.44)。
- GDF-15每翻倍与CKD进展(HR 1.30)和全因死亡(HR 1.72)独立相关。
- GDF-15与握力和肌酐肌肉指数负相关,与BMI无关。
核心结论
- 在非透析CKD患者中,循环GDF-15浓度升高与食欲差、肌少症标志物、CKD进展及全因死亡独立相关。
研究设计与样本
- NURTuRE-CKD为前瞻性多中心队列研究,纳入2996例非透析依赖CKD患者,基线测量GDF-15并问卷评估食欲,纵向 ascertain CKD进展和全因死亡。
主要发现
- GDF-15在2929例中可测,中位浓度2503 pg/ml(IQR 1605-3851)。
- 食欲差者(n=786,27%)GDF-15更高(2965 vs 2350 pg/ml;P<0.001)。
- 校正后GDF-15每翻倍与食欲差风险相关(OR 1.44,95%CI 1.28-1.62)。
- GDF-15与握力(ρ=-0.18;P<0.001)和肌酐肌肉指数(ρ=-0.40;P<0.001)负相关,与BMI无关。
- 中位随访50(41-56)个月,893例(32%)CKD进展,527例(18%)死亡;GDF-15每翻倍调整HR:CKD进展1.30(95%CI 1.18-1.42),全因死亡1.72(95%CI 1.58-1.89)。
临床怎么用
- 在非透析CKD患者中,GDF-15升高提示食欲差、肌少症及不良预后风险,可辅助风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Anorexia is common in chronic kidney disease (CKD), yet the underlying mechanisms remain poorly defined. Growth differentiation factor-15 (GDF-15) suppresses appetite in cancer, where anti-GDF-15 therapy improves appetite. METHODS: NURTuRE-CKD is a prospective, multicentre cohort study of 2996 individuals with non-dialysis-dependent CKD. At baseline, circulating GDF-15 was measured and appetite was assessed using a questionnaire. Muscle function and estimated muscle mass were evaluated using handgrip strength (kg) and creatinine muscle index (estimated glomerular filtration rate [eGFR] cystatinC × serum creatinine). CKD progression (≥ 40% decline in eGFR, incident eGFR < 15 ml/min per 1.73 m2, or dialysis initiation) and all-cause mortality were ascertained longitudinally. Multivariable logistic regression evaluated associations between GDF-15 and poor appetite, adjusting for eGFR, urea, nutritional and metabolic markers, CRP, comorbidities, and smoking. Cox models assessed associations with CKD progression (adjusted for Kidney Failure Risk Equation components) and all-cause mortality (additionally adjusted for CRP, comorbidities, and smoking). RESULTS: GDF-15 was measured in 2929 participants. The median concentration was 2503 pg/ml (interquartile range 1605-3851). Participants with poor appetite (n = 786, 27%) had higher GDF-15 (2965 vs. 2,350 pg/ml; P < 0.001). In adjusted analyses, each doubling of GDF-15 was associated with higher odds of poor appetite (odds ratio [OR] 1.44, 95% CI 1.28-1.62). GDF-15 correlated negatively with handgrip strength (ρ = -0.18; P < 0.001) and creatinine muscle index (ρ= -0.40; P < 0.001), but not with body mass index. Over a median follow-up of 50 (41-56) months, 893 (32%) experienced CKD progression and 527 (18%) died. Adjusted hazard ratios per doubling of GDF-15 were 1.30 (95% CI, 1.18-1.42) for CKD progression and 1.72 (95% CI, 1.58-1.89) for all-cause mortality. CONCLUSION: Among individuals with non-dialysis CKD, higher circulating GDF-15 concentrations were independently associated with poor appetite, sarcopenia markers, CKD progression, and all-cause mortality.
引用
- McDonnell T, Hayward S, Vuilleumier N, et al. Associations of Growth Differentiation Factor 15 in Chronic Kidney Disease. Kidney Int Rep. 2026. PMID: 42733545. doi:10.1016/j.ekir.2026.106995
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。